We're joined today by Ivan Kairatov, a biopharma expert whose work at the intersection of technology and R&D provides a unique lens on the future of oncology. While immune checkpoint inhibitors have revolutionized cancer treatment, the stark reality is that most patients don't respond, largely due
For individuals living with debilitating genetic skin disorders, effective treatments have remained elusive, often limited to managing symptoms rather than addressing the root cause encoded in their DNA. A groundbreaking development from researchers at the University of British Columbia and the
The treatment paradigm for bladder cancer is undergoing a seismic shift, as a new wave of clinical research moves beyond traditional protocols to pioneer a more integrated, intelligent, and immune-focused approach to care. This evolution is not merely about refining existing methods but about
While the dangers of heavy drinking are widely acknowledged, a landmark study has now illuminated the profound and cumulative risk that a lifetime of alcohol consumption poses for the development of colorectal cancer. Moving beyond simple snapshots of current habits, this comprehensive analysis
A new wave of philanthropic investment is poised to transform how society supports individuals facing the end of life, moving beyond the traditional focus on managing physical pain to directly address the profound emotional and existential suffering that often accompanies a terminal diagnosis. This
Today we’re joined by Ivan Kairatov, a biopharma expert with deep experience in drug development and the intricate dance between innovation, regulation, and market perception. We'll be dissecting the recent developments with Intellia Therapeutics, a pioneer in CRISPR gene editing. The company has
